Kura Oncology Stock Target Price and Analyst Consensus
| KURA Stock | USD 17.68 0.31 1.72% |
The current analyst and expert consensus on Kura Oncology is Strong Buy, with 10 strong buy opinions. The current projected Kura Oncology target price consensus is 29.88 with 14 analyst opinions. The most common way Kura Oncology analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Kura Oncology executives and customers to further validate their buy or sell advice. Kura Oncology buy-or-sell recommendation module provides average expert sentiment on the projected Kura Oncology target price to derive its highest and lowest estimates based on its projected price volatility. Check out Macroaxis Advice on Kura Oncology to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.
Lowest Forecast 27.19 | Highest Forecast 33.17 | Target Price 29.88 |
Kura |
It's important to approach Kura Oncology's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Kura Oncology Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kura target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Kura Oncology's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 14 | Strong Buy |
Most Kura analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Kura stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Kura Oncology, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationKura Oncology Target Price Projection
Kura Oncology's current and average target prices are 17.68 and 29.88, respectively. The current price of Kura Oncology is the price at which Kura Oncology is currently trading. On the other hand, Kura Oncology's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Kura Oncology Market Quote on 18th of April 2024
Target Price
Analyst Consensus On Kura Oncology Target Price
Kura Oncology Analyst Ratings
Kura Oncology's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Kura Oncology stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Kura Oncology's financials, market performance, and future outlook by experienced professionals. Kura Oncology's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Kura Oncology price targets
Kura Oncology's stock target price is an estimate of its future price, usually made by analysts. Using Kura Oncology's target price to determine if it is a suitable investment can be done through the following steps:- Look at Kura Oncology's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Kura Oncology's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Kura Oncology Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Kura Oncology is a key component of Kura Oncology valuation and have some predictive power on the future returns of a Kura Oncology.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kura Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested over 70 shares | |
 | Manufacturing Invested over 40 shares | |
 | Automobiles and Trucks Invested over 200 shares | |
 | Banking Invested over 30 shares | |
 | Blockchain Invested few shares | |
 | Power Assets Invested over 200 shares | |
Check out Macroaxis Advice on Kura Oncology to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
The data published in Kura Oncology's official financial statements usually reflect Kura Oncology's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kura Oncology. For example, before you start analyzing numbers published by Kura accountants, it's critical to develop an understanding of what Kura Oncology's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Kura Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kura Oncology's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kura Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kura Oncology. Please utilize our Beneish M Score to check the likelihood of Kura Oncology's management manipulating its earnings.